首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2421篇
  免费   0篇
电工技术   1篇
化学工业   16篇
金属工艺   2篇
机械仪表   11篇
建筑科学   1篇
轻工业   3篇
无线电   8篇
一般工业技术   6篇
冶金工业   2365篇
原子能技术   2篇
自动化技术   6篇
  2022年   1篇
  2021年   1篇
  2020年   1篇
  2018年   1篇
  2017年   1篇
  2014年   3篇
  2013年   1篇
  2012年   1篇
  2011年   3篇
  2010年   2篇
  2009年   4篇
  2008年   1篇
  2007年   2篇
  2006年   4篇
  2005年   2篇
  2004年   1篇
  2003年   3篇
  2002年   1篇
  2001年   1篇
  1999年   76篇
  1998年   709篇
  1997年   443篇
  1996年   275篇
  1995年   149篇
  1994年   130篇
  1993年   147篇
  1992年   13篇
  1991年   25篇
  1990年   26篇
  1989年   25篇
  1988年   22篇
  1987年   17篇
  1986年   13篇
  1985年   18篇
  1983年   6篇
  1982年   14篇
  1981年   8篇
  1980年   27篇
  1979年   4篇
  1978年   10篇
  1977年   64篇
  1976年   159篇
  1975年   5篇
  1964年   1篇
  1955年   1篇
排序方式: 共有2421条查询结果,搜索用时 15 毫秒
981.
982.
983.
The carcinogenic potential of the nonsteroidal triphenylethylene antiestrogen toremifene (Fareston) was evaluated in a standard 104-week rat dietary carcinogenicity study. The doses were 0, 0.12, 1.2, 5.0 and 12 mg/kg/day and the number of animals 50/sex/dose group. The body weight gain and food consumption were monitored once weekly (study weeks 1-16) or once every four weeks thereafter (study weeks 17-104). Blood samples were taken at weeks 34, 52 and 104 and the plasma concentrations of toremifene, as well as the two main metabolites (deaminohydroxy)toremifene and N-demethyltoremifene, were measured. All doses of toremifene reduced food intake and body weight gain. Toremifene caused a significant reduction in mortality, which was mainly due to reduced incidences of pituitary tumors. This was evident in all dose groups. Drug-related decrease of mammary tumors in females (at all doses) and testicular tumors in male rats (doses > or = 1.2 mg/kg/day) were also evident. The incidence of the preneoplastic foci of basophilic hepatocytes were significantly decreased in treated female groups. Toremifene induced no preneoplastic or neoplastic lesions. Based on histopathology, no obvious toxicity could be observed. Drug-related changes were observed in the genital organs, thyroid, spleen, mammary gland, adrenal, kidney, stomach and lung. These changes were due to hormonal disturbances or as a result of reduced food consumption or reduced incidences of pituitary, mammary or testicular tumors. This study indicates that toremifene is an efficient antiestrogen in long-term treatment, is well tolerated and has no tumorigenic potential in rats.  相似文献   
984.
985.
986.
Polymeric compounds of the cell walls of Act. rimosus were studied during the actinomycete growth. It was found that the content of teichoic acid decreased 2 times by the end of development of Act. rimosus, while content of glycane polymer remained approximately at the same level. The molar ratios of teichoic acid and glycopeptide glycane were determined.  相似文献   
987.
988.
989.
990.
Glycosyl-phosphatidylinositol (GPI) lipids have a structural role as protein anchors to the cell surface. In addition, they are implicated in hormone, growth factor and cytokine signal transduction. Their phosphodiesteric hydrolysis mediated by an activated phospholipase results in the generation of water soluble oligosaccharide species termed the inositol phosphoglycan (IPG). This product has been demonstrated to possess biological properties when added exogenously to cells mimicking the biological effects of a variety of extracellular ligands. This may be accomplished since IPG is generic for a family of closely related species which are released in a tissue-specific manner and additionally have cell-specific targets. Micro-organic synthesis has recently been able to shed new light on this topic by the introduction of defined oligosaccharide analogues of IPG for the assessment of their biological activity. These have complemented the findings observed with purified IPG from biological sources thus strengthening the belief that the GPI/IPG signalling system represents a truly novel aspect of transmembrane signalling.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号